Collegium Pharmaceutical, Inc. COLL
- Market cap
- $737.1M
- P/E
- 14.7×
Follow COLL
Target Price Range
Analyst price targets
Free account| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 8.24 | 7.37 | 13.70 | 10.01 | 13.00 | 17.22 | 14.04 | 20.83 | 28.47 | 23.23 |
Analyst estimates 2026–2028 Powerpack |
Low Price
|
||
| 28.47 | 20.92 | 29.90 | 22.28 | 25.59 | 26.91 | 24.36 | 31.12 | 42.29 | 50.79 |
High Price
|
|||
| 234 | 250 | 266 | 255 | 234 | 152 | 207 | 197 | 357 | 423 |
Employees
|
|||
| 0 | 0 | 1 | 1 | 1 | 2 | 2 | 3 | 2 | 2 |
Revenue/Emp
|
|||
| 2 | 28 | 280 | 297 | 310 | 277 | 464 | 567 | 631 | 781 |
Revenue
|
|||
| 87.55% | 90.89% | 40.92% | 34.73% | 58.01% | 54.40% | 45.15% | 57.55% | 59.76% | 59.35% |
Gross Margin
|
|||
| (94) | (75) | (39) | (23) | 28 | (3) | (29) | 76 | 99 | 93 |
EBT
|
|||
| (5,504.15%) | (262.91%) | (13.95%) | (7.66%) | 8.90% | (1.22%) | (6.22%) | 13.36% | 15.61% | 11.87% |
EBT Margin
|
|||
| (94) | (75) | (39) | (23) | 27 | 72 | (25) | 48 | 69 | 63 |
Net Income
|
|||
| 1 | 1 | 111 | 15 | 62 | 69 | 139 | 148 | 167 | 225 |
Depreciation
|
|||
| 0.07 | 0.94 | 8.51 | 8.87 | 9.01 | 7.92 | 13.71 | 16.80 | 19.57 | 24.62 |
Revenue/Sh
|
|||
| (3.88) | (2.47) | (1.19) | (0.68) | 0.78 | 2.05 | (0.74) | 1.43 | 2.14 | 1.98 |
Earnings/Sh
|
|||
| (3.09) | (2.21) | 5.14 | 0.83 | 2.73 | 2.96 | 3.67 | 8.14 | 6.35 | 10.39 |
Cash Flow/Sh
|
|||
| (0.02) | (0.03) | (0.74) | (0.19) | (10.86) | (0.06) | (0.05) | (0.01) | (0.05) | (0.05) |
Capex/Sh
|
|||
| (3.11) | (2.25) | 4.40 | 0.64 | (8.13) | 2.91 | 3.62 | 8.13 | 6.30 | 10.33 |
Free CF/Sh
|
|||
| 5.56 | 3.44 | 2.78 | 2.61 | 5.41 | 5.81 | 5.76 | 5.79 | 7.09 | 9.51 |
Book Value/Sh
|
|||
| 24 | 30 | 33 | 33 | 34 | 35 | 34 | 34 | 32 | 32 |
Shares
|
|||
| 0.00 | 0.00 | 0.00 | 0.00 | 26.01 | 9.29 | 0.00 | 21.24 | 13.39 | 23.15 |
PE Ratio
|
|||
| 0.00 | 19.87 | 2.02 | 2.32 | 2.22 | 2.36 | 1.72 | 1.86 | 1.46 | 1.88 |
PS Ratio
|
|||
| 2.82 | 5.44 | 6.18 | 7.87 | 3.70 | 3.22 | 4.09 | 5.39 | 4.04 | 4.87 |
PB Ratio
|
|||
| 0.00 | 15.77 | 1.54 | 1.79 | 2.49 | 2.59 | 2.86 | 2.49 | 2.52 | 2.40 |
EV/Sales
|
|||
| (3.06) | (6.60) | 3.02 | (16,561.38) | (2.76) | (2.69) | (5.39) | (15.01) | (9.64) | (46.03) |
EV/FCF
|
|||
| (75) | (67) | 169 | 28 | 94 | 104 | 124 | 275 | 205 | 329 |
Op' Cash Flow
|
|||
| 0 | (1) | (24) | (6) | (374) | (2) | (2) | 0 | (2) | (2) |
Capex
|
|||
| (76) | (68) | 145 | 21 | (280) | 102 | 123 | 274 | 203 | 328 |
FCF
|
|||
| 133 | 102 | 48 | 54 | 38 | 36 | (14) | 80 | (27) | 251 |
Working Cap'
|
|||
| 4 | 1 | 12 | 12 | 257 | 250 | 701 | 667 | 852 | 809 |
Total Debt
|
|||
| (149) | (117) | (135) | (159) | 83 | 64 | 527 | 357 | 665 | 403 |
Net Debt
|
|||
| 135 | 104 | 92 | 87 | 186 | 203 | 195 | 195 | 229 | 302 |
Sh' Equity
|
|||
| (72.52%) | (50.32%) | (18.33%) | (7.61%) | 5.63% | 10.71% | (2.68%) | 4.16% | 4.93% | 3.79% |
ROA
|
|||
| 0.00% | 0.00% | 0.00% | 0.00% | 13.06% | 4.13% | 2.88% | 18.90% | 11.88% | 15.94% |
ROIC
|
|||
| (85.62%) | (62.65%) | (39.99%) | (25.39%) | 19.57% | 36.77% | (12.57%) | 24.68% | 32.62% | 23.70% |
ROE
|
|||
Collegium Pharmaceutical, Inc. peers in Drug Manufacturers Specialty & Generic
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| IRWD Ironwood Pharmaceuticals, Inc. | $692.4M | 5.2× | Compare |
| AQST Aquestive Therapeutics, Inc. | $605.0M | 0.0× | Compare |
| TLRY Tilray Brands, Inc. | $603.0M | 0.0× | Compare |
| EVO Evotec AG | $539.9M | 0.0× | Compare |
| Company | Market cap | P/E | Compare |
|---|---|---|---|
| PCRX Pacira BioSciences, Inc. | $1.0B | 71.8× | Compare |
| EOLS Evolus, Inc. | $519.2M | 0.0× | Compare |
| KMDA Kamada Ltd. | $509.4M | 22.9× | Compare |
| TKNO Alpha Teknova, Inc. | $498.8M | 0.0× | Compare |
Collegium Pharmaceutical, Inc. (COLL) key facts
- Collegium Pharmaceutical, Inc. (COLL) is a Drug Manufacturers Specialty & Generic company in the Healthcare sector, listed on Nasdaq.
- Collegium Pharmaceutical, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $780.6 million, up 23.6% from fiscal 2024.
- Net income was $62.9 million, or $1.98 per share (basic), a net margin of 8.05%.
- As of September 25, 2026, COLL traded at $22.53, a market capitalization of $737.1 million.
- At that price the stock trades at 14.7× trailing-twelve-month earnings and 0.9× sales.
- Return on equity was 23.7% and debt-to-equity 3.50.
Collegium Pharmaceutical, Inc. (COLL) Latest News
22 Sep
StockStory flags Collegium Pharmaceutical (COLL) as a risky name in a segment prone to volatility. COLL develops abuse-deterrent opioid formulations for moderate-to-severe pain but carries a small revenue base (~$808 million) with 3.4% projected sales growth next year. Expenses have risen as a share of revenue, pushing adjusted operating margins down 7.6 percentage points over the past two years. At $23.33 per share, the stock trades around 3.3x forward earnings, signaling limited scale benefits and a potentially fragile profitability path. The piece suggests caution on COLL, urging readers to review a free research report before considering exposure. Slower growth, rising costs, and a small revenue base imply a meaningful but not transformative drag on COLL's trajectory.
15 Aug
Collegium Pharmaceutical’s Q2 earnings call drew analyst questions on revenue trends, product pipeline progress, competitive pressures, and future guidance. Analyst questions from the earnings call offer moderate insight into strategy and outlook that can influence near-term sentiment without signaling major shifts.
13 Aug
Collegium Pharmaceutical released its Q2 2026 earnings call transcript covering financial results, operational updates and forward outlook. Earnings call transcripts deliver core quarterly metrics and guidance that move investor views and valuation.
Collegium Pharmaceutical launches $50 million accelerated share repurchase program. Buyback reduces share count and may lift EPS but leaves core operations unchanged.
9 Aug
Collegium Pharmaceutical expands ADHD portfolio while pain business headwinds shape Q2 guidance and outlook. ADHD expansion and pain business headwinds reshape guidance and market trajectory.
6 Aug
Collegium Pharmaceutical's Q2 2026 earnings call highlights a surge in its ADHD portfolio. ADHD portfolio surge signals major revenue growth and strengthened market position for Collegium Pharmaceutical.
Collegium Pharmaceutical Q2 earnings call highlights revenue, profit metrics, product sales, and management guidance on operations and growth. Q2 earnings results and forward guidance directly affect stock valuation and investor positioning.
Collegium Pharmaceutical, Inc. held its Q2 2026 earnings call covering financial results and operations. Standard quarterly earnings update may sway near-term sentiment but does not signal major strategic or competitive changes.
Collegium Pharmaceutical (COLL) released Q2 earnings with key metrics compared against estimates. Q2 earnings metrics versus estimates can moderately sway financial outlook and investor sentiment.
Collegium Pharmaceutical beat Q2 earnings and revenue estimates. Beating quarterly estimates typically supports short-term stock gains and market sentiment.
19 Jul
Collegium Pharmaceutical maintains its growth trajectory, prompting evaluation of whether the stock remains undervalued. Sustained growth narrative may moderately shift investor views on valuation without major operational changes.
27 May
Collegium Pharmaceutical Inc. (COLL) stock gains attention due to its ADHD portfolio. ADHD portfolio focus may moderately influence COLL competitive positioning and investor sentiment.
18 May
Collegium Pharmaceutical reported Q1 results and addressed top analyst questions on financial performance, product strategy, and outlook during its earnings call. Q1 earnings updates and analyst questions deliver moderate insights into operations and outlook that can influence near-term stock sentiment.
14 May
Collegium Pharmaceutical (NASDAQ:COLL) delivered solid earnings reinforced by other strong factors. Solid earnings and supporting strong factors signal significant positive influence on financial performance and investor sentiment.
13 May
Analysts single out Collegium Pharmaceutical (COLL) as a healthcare stock with strong competitive advantages while dismissing two others. Positive analyst highlighting of competitive advantages likely to moderately influence investor sentiment and stock performance.
12 May
Collegium Pharmaceutical, Inc. (COLL) completed its acquisition of AZSTARYS®, an ADHD treatment, from Corium Therapeutics, expanding its neuroscience portfolio. Acquisition of AZSTARYS adds a revenue-generating ADHD product to Collegium's portfolio, strengthening its market position and growth trajectory.
11 May
Collegium Pharmaceutical (COLL) delivered strong Q1 results driven by ADHD portfolio expansion and stability in the pain segment. ADHD portfolio expansion marks a major strategic advance with potential to significantly boost revenue and market position.
7 May
Collegium Pharmaceutical, Inc. (COLL) released Q1 2026 earnings call summary detailing quarterly financial performance, operational updates, and forward guidance. Q1 2026 earnings call summary discloses financial results and strategic outlook that significantly influence COLL's stock trajectory and investor sentiment.
Collegium Pharmaceutical, Inc. (COLL) released its Q1 2026 earnings call transcript detailing quarterly financial results, operational updates, and forward guidance. Q1 2026 earnings transcript discloses financial performance, revenue figures, and strategic outlook significantly influencing COLL's market trajectory and investor sentiment.
Collegium Pharmaceutical, Inc. (COLL) released Q1 earnings call highlights covering financial performance, revenue growth, product updates, and forward guidance. Q1 earnings highlights detail financial results, operational progress, and strategic outlook significantly shaping investor expectations and stock trajectory.
Collegium Pharmaceutical (COLL) Q1 earnings and revenues beat analyst estimates. Q1 earnings and revenue beats demonstrate strong financial results, likely driving positive investor sentiment and stock performance.
Collegium Pharmaceutical (NASDAQ:COLL) exceeded Q1 CY2026 expectations, driving its stock to soar. Exceeding Q1 CY2026 expectations triggered a stock surge, signaling strong financial performance and boosting investor sentiment.
Collegium Pharmaceutical, Inc. (COLL) reported first quarter 2026 financial results and highlighted recent company progress. Quarterly earnings reports directly drive stock volatility and shape investor expectations for future performance.
Collegium Pharmaceutical (COLL) Q1 earnings report analyzes key metrics against analyst estimates. Q1 earnings metrics versus estimates affect financial performance and investor sentiment moderately.
30 Apr
Collegium Pharmaceutical (COLL) Q1 earnings expected to decline. Expected Q1 earnings decline could noticeably impact financial performance and investor sentiment.
15 Apr
Collegium Pharmaceutical announced its 2026 revenue outlook and detailed a $650 million AZSTARYS licensing deal at the Needham Healthcare Conference. $650M AZSTARYS deal and 2026 revenue outlook represent major strategic revenue expansion.
27 Mar
Collegium Pharmaceutical announces AZSTARYS deal amid insider sale, shifting investor focus to company valuation. AZSTARYS deal advances strategic product portfolio while insider sale triggers valuation scrutiny and potential market volatility.
19 Mar
Collegium Pharmaceutical, Inc. (COLL) to acquire AZSTARYS from Corium for $650 million in cash, expanding its ADHD franchise with rights through 2037. The $650 million AZSTARYS acquisition represents a major strategic expansion of Collegium's ADHD portfolio through 2037, significantly boosting growth prospects.
Collegium Pharmaceutical, Inc. (COLL) to acquire AZSTARYS® from Corium Therapeutics, bolstering ADHD position and accelerating growth trajectory. Acquisition of AZSTARYS expands Collegium's ADHD portfolio, enhancing competitive positioning and growth prospects.
14 Mar
Collegium Pharmaceutical reported record 2025 results and expects JORNAY PM to drive 2026 growth, as stated at the Barclays Miami Conference. Record 2025 performance and JORNAY PM growth projections signal significant positive impact on future financials and investor sentiment.